MyFiziq cash swells to $1.8M with more revenues in the pipeline
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
MyFiziq Limited (ASX:MYQ) has received the tranche 3 payment of US$450,000 under the convertible note subscription deed announced with Asia Cornerstone Asset Management (ACAM).
Management noted that the payment has been received two weeks ahead of schedule.
As announced in June, under the terms of the Convertible Note Subscription Deed with ACAM, MyFiziq will receive a total of US$1.5 million in 4 tranches, with tranche 3 of US$450,000 now received.
The final tranche of US$375,000 will become available after the company engages an underwriter or an investment bank to provide services in connection with the proposed NASDAQ listing.
Income received for application usage and development
MyFiziq has been quick to form partnership agreements that will help to broaden the reach of its body measurement technology and the group has started to receive income related to these initiatives.
More recently, revenues have been received for the application usage and direct development of their application integrations.
Management highlighted that the company has received more than $1 million in funding from ACAM and the group’s partners.
In addition, the NASDAQ initiative is progressing well with the company on track to file the Registration Statement (Form F-1) with the US Securities and Exchange Commission in the coming weeks.
Commenting on the positive impact these developments are having on MyFiziq’s financial position, chief financial officer Stephen Richards said, “We continue to bolster the company’s cash position with the ACAM funding along with partner payments received to the tune of $382,139.
‘’This increases the company’s cash at bank balance at the time of this release to $1,792,786, as the company continues to strengthen its balance sheet.
‘’We are expecting further partner payment in the region of $280,000 and the second instalment of the BCT license fee in the order of $200,000 in the month of July.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
